ClinicalTrials.Veeva

Menu

Effectiveness of the Cytokine Hemadsorption on Sepsis

B

Biruni University

Status

Completed

Conditions

Interleukin-6

Treatments

Procedure: cytokine hemadsorption

Study type

Observational

Funder types

Other

Identifiers

NCT05057455
BIRUNI 2

Details and patient eligibility

About

In this prospective study, we aimed to compare the laboratory and clinical results of cytokine hemadsorption as an immunomodulation therapy in ICU patients diagnosed with sepsis or septic shock.

Enrollment

39 patients

Sex

All

Ages

18 to 100 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • the patients were the available data of clinical and laboratory diagnosis of sepsis and septic shock
  • detection of gram-negative bacterial agent in blood or sputum culture.
  • patients who had the shock symptoms such as hypotension, tachycardia or fever during the course of sepsis.

Exclusion criteria

  • had uncontrolled hemorrhage,
  • diagnosed with cardiac failure at stage 4 or renal failure at stage 4 or hepatic liver failure at stage 4
  • cancer at the end stage or admitted with acute coronary syndrome.

Trial design

39 participants in 1 patient group

ICU patients diagnosed with sepsis or septic shock
Description:
compare the laboratory and clinical results of cytokine hemadsorption as an immunomodulation therapy in ICU patients diagnosed with sepsis or septic shock.
Treatment:
Procedure: cytokine hemadsorption

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems